MDS Global Launches an AI-powered Marketing Decision Intelligence Platform “MDS DecisionAI” That Enables Telcos to Reduce Churn and Increase Revenues
31.5.2023 09:22:00 EEST | Business Wire | Press release
Today, MDS Global, a leading provider of converged B2B/B2C billing and BSS solutions, has launched MDS DecisionAI, a new marketing decision intelligence platform that leverages the power of artificial intelligence to provide the critical insight ambitious MNOs, MVNOs, sub-brands and fixed line operators need to grow and outperform the competition.
MDS DecisionAI provides a full suite of telecoms specific AI modules including forecasting, churn, propensity models, and marketing and media mix analysis, that will help brands to optimise their marketing and commercial strategy. It enables them to identify monetisation opportunities and blind spots so they can make interventions sooner.
As a result, operators will be able to maximise yield and revenue, for example by predicting churn and identifying a customer’s propensity to consider other products offered in a cross-sell campaign, or through better-informed proposition development.
As part of MDS Global’s commitment to driving profitable digital telcos, MDS DecisionAI’s SaaS model, makes it a highly flexible and affordable way to operationally deploy AI. This is particularly beneficial for operators, MVNOs and sub brands who haven’t been able to invest in AI in the past due to the complexity of implementation, high integration costs and lack of affordable expert skill. The model eliminates the need for complex, costly and lengthy implementation projects. Instead, it can be easily integrated into existing billing, CVM and digital channels, no matter the platform used. Operators can expect to be set up and reaping the benefits of making more informed strategic decisions within 60 days.
Decision intelligence tools are changing the shape of telecoms with reports of cases where operators have made multi-million-pound revenue improvements from a more reactive churn response, seen 25% increase on cross sell success rates, and 30% uplift in acquisition by reviewing marketing media spend.
John Burton, CEO of MDS Global, says MDS DecisionAI will democratise artificial intelligence and decision intelligence, and make it accessible to all, including small brands: “Only 5%1 of telcos have a full AI marketing and personalisation strategy that is delivering an ROI on expected growth and benefits. MDS DecisionAI is a game changer and makes the vision of becoming a profitable digital telco more achievable.”
“Using MDS DecisionAI will create more agile and successful operators almost overnight. The use of AI will help them make the right commercial and marketing spending decisions and make more informed decisions about when and how to adjust their strategy or invest in innovation.”
More information about how AI is changing the telco landscape and supporting digital telco strategies is available here. Operators can also request a demo here.
About MDS Global
MDS Global is a leading provider of converged B2B/B2C billing and BSS solutions to MNOs, MVNOs, MVNEs and fixed line telcos. We power our customers’ transition from connectivity providers to digital service providers with carrier-grade solutions that include our cloud monetisation platform, AI-powered marketing decision intelligence platform, eSIM, and self-care apps portals.
Our agile “No code” SaaS solutions enable communications service providers to drive profit growth, deliver delightful digital customer experiences and launch innovative services fast.
To find out more, visit www.mdsglobal.com or follow us on LinkedIn and Twitter .
1 Unlocking the value of personalization at scale for operators, McKinsey, February 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005875/en/
Contact information
MDS Global press contact
Corine Suscens
Head of Global Marketing
marketing@mdsglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom